JP7600240B2 - Ｐｓｍａに結合する抗原結合ドメイン - Google Patents

Ｐｓｍａに結合する抗原結合ドメイン Download PDF

Info

Publication number
JP7600240B2
JP7600240B2 JP2022537008A JP2022537008A JP7600240B2 JP 7600240 B2 JP7600240 B2 JP 7600240B2 JP 2022537008 A JP2022537008 A JP 2022537008A JP 2022537008 A JP2022537008 A JP 2022537008A JP 7600240 B2 JP7600240 B2 JP 7600240B2
Authority
JP
Japan
Prior art keywords
seq
cells
antigen
psma
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022537008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507740A (ja
JP2023507740A5 (https=
Inventor
シモビ オヌオハ，
マテュー フェラーリ，
ペルタ， マルコ デラ
アレクサンダー キンナ，
ショーン コルドバ，
Original Assignee
オートラス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オートラス リミテッド filed Critical オートラス リミテッド
Publication of JP2023507740A publication Critical patent/JP2023507740A/ja
Publication of JP2023507740A5 publication Critical patent/JP2023507740A5/ja
Priority to JP2024200599A priority Critical patent/JP2025015730A/ja
Application granted granted Critical
Publication of JP7600240B2 publication Critical patent/JP7600240B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022537008A 2019-12-20 2020-12-18 Ｐｓｍａに結合する抗原結合ドメイン Active JP7600240B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024200599A JP2025015730A (ja) 2019-12-20 2024-11-18 Ｐｓｍａに結合する抗原結合ドメイン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1919019.8 2019-12-20
GBGB1919019.8A GB201919019D0 (en) 2019-12-20 2019-12-20 Antigen-binding domain
PCT/GB2020/053289 WO2021123810A1 (en) 2019-12-20 2020-12-18 Antigen-binding domain binding to psma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024200599A Division JP2025015730A (ja) 2019-12-20 2024-11-18 Ｐｓｍａに結合する抗原結合ドメイン

Publications (3)

Publication Number Publication Date
JP2023507740A JP2023507740A (ja) 2023-02-27
JP2023507740A5 JP2023507740A5 (https=) 2023-10-26
JP7600240B2 true JP7600240B2 (ja) 2024-12-16

Family

ID=69322734

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022537008A Active JP7600240B2 (ja) 2019-12-20 2020-12-18 Ｐｓｍａに結合する抗原結合ドメイン
JP2024200599A Pending JP2025015730A (ja) 2019-12-20 2024-11-18 Ｐｓｍａに結合する抗原結合ドメイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024200599A Pending JP2025015730A (ja) 2019-12-20 2024-11-18 Ｐｓｍａに結合する抗原結合ドメイン

Country Status (8)

Country Link
US (1) US12496314B2 (https=)
EP (1) EP4076509A1 (https=)
JP (2) JP7600240B2 (https=)
CN (1) CN114828879A (https=)
AU (1) AU2020406862A1 (https=)
CA (1) CA3161844A1 (https=)
GB (1) GB201919019D0 (https=)
WO (1) WO2021123810A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240228620A1 (en) 2022-10-06 2024-07-11 Bicara Therapeutics Inc. Multispecific proteins and related methods
KR20250133776A (ko) 2023-02-10 2025-09-08 아뮤닉스 파마슈티컬스, 인크. 전립선-특이적 막 항원(psma)을 표적화하는 조성물 및 이의 제조 방법 및 사용 방법
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016111344A1 (ja) 2015-01-08 2016-07-14 協和発酵キリン株式会社 Ｔｒａｉｌｒ２とｐｓｍａに結合するバイスペシフィック抗体
US20190144561A1 (en) 2016-05-06 2019-05-16 Crescendo Biologics Limited Chimeric antigen receptor with single domain antibody
JP2019523651A (ja) 2016-04-13 2019-08-29 オリマブス リミテッド 抗ｐｓｍａ抗体およびその使用
WO2019173636A1 (en) 2018-03-07 2019-09-12 Poseida Therapeutics, Inc. Cartyrin compositions and methods for use
WO2019173324A1 (en) 2018-03-06 2019-09-12 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
EP2571992B1 (en) * 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201503133D0 (en) 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein
CN108640999B (zh) 2018-03-27 2021-08-13 广东万海细胞生物科技有限公司 一种靶向表达psma表面抗原的细胞的嵌合抗原受体
CN110526984A (zh) 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 一种靶向psma的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
CN110526976A (zh) 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 一种靶向psma的单链抗体、嵌合抗原受体t细胞及其制备方法和应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016111344A1 (ja) 2015-01-08 2016-07-14 協和発酵キリン株式会社 Ｔｒａｉｌｒ２とｐｓｍａに結合するバイスペシフィック抗体
JP2019523651A (ja) 2016-04-13 2019-08-29 オリマブス リミテッド 抗ｐｓｍａ抗体およびその使用
US20190144561A1 (en) 2016-05-06 2019-05-16 Crescendo Biologics Limited Chimeric antigen receptor with single domain antibody
WO2019173324A1 (en) 2018-03-06 2019-09-12 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
WO2019173636A1 (en) 2018-03-07 2019-09-12 Poseida Therapeutics, Inc. Cartyrin compositions and methods for use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. Cell Biochem.，2019年，Vol.120，pp.10787-10795，(First published: 2019.1.22)
Molecular Therapy，2018年，Vol.26, No.7，pp.1855-1866, Suppl. Info.
PLoS ONE，2014年，Vol.9, No.10, e109427，pp.1-12

Also Published As

Publication number Publication date
WO2021123810A1 (en) 2021-06-24
EP4076509A1 (en) 2022-10-26
CN114828879A (zh) 2022-07-29
JP2023507740A (ja) 2023-02-27
JP2025015730A (ja) 2025-01-30
US12496314B2 (en) 2025-12-16
GB201919019D0 (en) 2020-02-05
AU2020406862A1 (en) 2022-06-16
CA3161844A1 (en) 2021-06-24
US20240252534A1 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
US12006371B2 (en) Humanized anti-MUC1* antibodies
JP2024024014A (ja) 受容体
EP3265490B1 (en) Chimeric antigen receptor (car) comprising a cd19-binding domain
CN107880128B (zh) 一种抗cd19的全人源抗体或抗体片段及其方法和应用
EP3414263B1 (en) Signalling system
JP2023143904A (ja) ヒト化抗ｍｕｃ１＊抗体及び開裂酵素の使用
JP2020074776A (ja) 抗ｇｐｃ３抗体
JP2025015730A (ja) Ｐｓｍａに結合する抗原結合ドメイン
CN109153731A (zh) 靶向bcma的嵌合抗原受体及其使用方法
WO2018193231A1 (en) Cell
JP2018523484A (ja) 細胞
CN118459606A (zh) 嵌合抗原受体
CN112912401A (zh) 抗-l1细胞粘附分子抗体或其抗原结合片段及包含其的嵌合抗原受体
CN111479918A (zh) 细胞
WO2021048564A2 (en) Antigen-binding domain
US20240141038A1 (en) Antibody against nkp46 and application thereof
CN116234559A (zh) 抗cd22单结构域抗体和治疗性构建体
US20250312453A1 (en) Antibody targeting ccr8 and its applications
Nannini Development of novel anti-mouse CD19 single-chain variable-fragments and establishment of an immunocompetent B-cell malignancy mouse model for the investigation of CAR-T cell therapies
WO2025133609A1 (en) Polypeptide binding glypican-3
WO2023078431A1 (zh) 一种特异性结合间皮素的合成t细胞受体抗原受体及其应用
JP2025539151A (ja) Ｌｉｌｒｂ４を特異的に結合する合成ｔ細胞受容体抗原受容体およびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231018

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241204

R150 Certificate of patent or registration of utility model

Ref document number: 7600240

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150